Dapagliflozin Triumphs in Cardiometabolic Outcomes Post Acute MI

The DAPA-MI trial, which investigated the use of dapagliflozin in acute myocardial infarction (MI) patients, showed significant improvements in cardiometabolic outcomes but did not have an impact on cardiovascular death or heart failure hospitalizations, the trial's original primary endpoint. The trial had to switch to a hierarchical win-ratio analysis due to low event rates, combining several clinical endpoints. The results suggest that dapagliflozin may have benefits in reducing the risk of developing heart failure, diabetes, hypertension, and other cardiometabolic conditions in acute MI patients. However, some experts remain skeptical about the implementation of dapagliflozin in this patient population, citing the modest absolute reductions in new diabetes diagnoses and weight loss.